Press Releases

LAWRENCEVILLE, N.J. , April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced that on April 10, 2024 , it

Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J. , March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported

Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J. , March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation

LAWRENCEVILLE, N.J. , March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m.

Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2 The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA   LAWRENCEVILLE, N.J. , March 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc .

Executive Chairman to lead day-to-day operations, active search underway for CEO successor. Timing of upcoming milestones for key programs remains unchanged.  LAWRENCEVILLE, N.J. , March 12, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc . (NASDAQ: IMNN) , a clinical-stage drug-development company focused on

Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality LAWRENCEVILLE, N.J. , Feb. 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc.  (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing

Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J. , Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation

Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J. , Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and